These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

52 related articles for article (PubMed ID: 2397644)

  • 21. Persistence and specificity of accessory cell impairment in M-MuLV neonatally injected mice.
    Biasi G; Saggin L; Dazzi F; Collavo D
    Transplant Proc; 1983 Dec; 15(4):2125-7. PubMed ID: 6608813
    [No Abstract]   [Full Text] [Related]  

  • 22. High numbers of tumour-infiltrating activated cytotoxic T lymphocytes, and frequent loss of HLA class I and II expression, are features of aggressive B cell lymphomas of the brain and testis.
    Riemersma SA; Oudejans JJ; Vonk MJ; Dreef EJ; Prins FA; Jansen PM; Vermeer MH; Blok P; Kibbelaar RE; Muris JJ; Schuuring EM; Kluin PM
    J Pathol; 2005 Jul; 206(3):328-36. PubMed ID: 15887291
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Major histocompatibility antigens and antigen-processing molecules in retinoblastoma.
    Krishnakumar S; Sundaram A; Abhyankar D; Krishnamurthy V; Shanmugam MP; Gopal L; Sharma T; Biswas J
    Cancer; 2004 Mar; 100(5):1059-69. PubMed ID: 14983503
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tolerance to class II major histocompatibility complex molecules is maintained in the presence of endogenous, interleukin-2-producing, tolerogen-specific T lymphocytes.
    Mohler KM; Streilein JW
    J Immunol; 1987 Oct; 139(7):2211-9. PubMed ID: 2958541
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
    Ritter M; Huber C; Auböck J; Pohl-Markl H; Troppmair J; Herold M; Gächter A; Nussbaumer W; Böck G; Nachbaur D
    Immunology; 1994 Apr; 81(4):569-77. PubMed ID: 7913694
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tolerance induction to skin allografts following intrathymic injection with donor-specific splenocytes in major histocompatibility complex class I, class I+MLS, and class I+II disparities.
    Ohzato H; Monaco AP
    Transplant Proc; 1993 Feb; 25(1 Pt 1):297-8. PubMed ID: 8438307
    [No Abstract]   [Full Text] [Related]  

  • 27. Activation of T cells by superantigen in class II-negative mice.
    Avery AC; Markowitz JS; Grusby MJ; Glimcher LH; Cantor H
    J Immunol; 1994 Dec; 153(11):4853-61. PubMed ID: 7963549
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Specificity, phenotype, and precursor frequency of primary cytolytic T lymphocytes specific for class II major histocompatibility antigens.
    Golding H; Singer A
    J Immunol; 1985 Sep; 135(3):1610-5. PubMed ID: 3874902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Isolation and characterization of monoclonal mouse cytotoxic T lymphocytes with specificity for HLA-A,B or -DR alloantigens.
    Engelhard VH; Benjamin C
    J Immunol; 1982 Dec; 129(6):2621-9. PubMed ID: 6982933
    [No Abstract]   [Full Text] [Related]  

  • 30. Analysis of the role of MHC class II presentation in the stimulation of cytotoxic T lymphocytes by antigens targeted into the exogenous antigen-MHC class I presentation pathway.
    Rock KL; Clark K
    J Immunol; 1996 May; 156(10):3721-6. PubMed ID: 8621907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anatomic location defines antigen presentation by dendritic cells to T cells in response to intravenous soluble antigens.
    Chung Y; Chang JH; Kim BS; Lee JM; Kim HY; Kang CY
    Eur J Immunol; 2007 Jun; 37(6):1453-62. PubMed ID: 17474148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of an Lyt-2+ alloreactive cytotoxic T cell clone specific for H-2Db that cross-reacts with I-Ek.
    Schilham MW; Lang R; Benner R; Zinkernagel RM; Hengartner H
    J Immunol; 1986 Nov; 137(9):2748-54. PubMed ID: 3489776
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Features of inducing cytotoxic T-lymphocytes, specific for a class I major histocompatibility molecule upon immunization into the foot pad].
    Azhipa OIa; Brondz BD
    Biull Eksp Biol Med; 1995 Feb; 119(2):190-3. PubMed ID: 7670050
    [No Abstract]   [Full Text] [Related]  

  • 34. Differential susceptibility of cytotoxic and helper T cell precursors to neonatal tolerization to histocompatibility antigens.
    Ishizaka ST; Carnaud C; Stutman O
    J Immunol; 1986 Oct; 137(7):2093-9. PubMed ID: 2944947
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD4+ T helper cell response is required for memory in CD8+ T lymphocytes induced by a poly(I:C)-adjuvanted MHC I-restricted peptide epitope.
    Qiu F; Cui Z
    J Immunother; 2007; 30(2):180-9. PubMed ID: 17471165
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of vaccinia virus expression vectors to investigate antigen processing and presentation.
    Wherry EJ; Rajagopal D; Eisenlohr LC
    Methods Mol Biol; 2001; 156():89-109. PubMed ID: 11068753
    [No Abstract]   [Full Text] [Related]  

  • 37. From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins.
    Krebs S; Rognan D
    Pharm Acta Helv; 1998 Dec; 73(4):173-81. PubMed ID: 9861866
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immunogenetics of autoimmune chronic active hepatitis.
    Eddleston AL
    Gastroenterol Jpn; 1993 Mar; 28 Suppl 4():57-62; discussion 76-80. PubMed ID: 8486231
    [No Abstract]   [Full Text] [Related]  

  • 39. Regulatory interactions between members of the immunoglobulin superfamily.
    Anderson P; Morimoto C; Breitmeyer JB; Schlossman SF
    Immunol Today; 1988; 9(7-8):199-203. PubMed ID: 3076415
    [No Abstract]   [Full Text] [Related]  

  • 40. Intracellular traffic and antigen processing.
    Long EO
    Immunol Today; 1989 Jul; 10(7):232-4. PubMed ID: 2679635
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.